WORLD-VAPERS’-ALLIANCE
30.6.2021 00:32:10 CEST | Business Wire | Press release
The World Vapers’ Alliance is today launching a major global campaign – ‘Back Vaping. Beat Smoking ’ - with the goal of shaping international public health policies and saving 200 million lives worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006043/en/
“The weight of research and real-world evidence shows that progressive vaping policies can help millions of smokers to quit. Yet vaping remains under threat as decision-makers face pressure from anti-vaping organisations. Our campaign will make sure the evidence and the voices of vapers are heard, so that Governments will take the opportunity to save 200 million lives”, said Michael Landl, Director of the World Vapers’ Alliance.
2021 is a critical year for public health policies globally. Two major milestones will determine if Governments grab the opportunity to save 200 million lives, or decide to limit smokers’ access to life-changing quit tools. The global ‘COP9’ conference will set the direction for anti-smoking and vaping policies worldwide. And the EU’s ‘Tobacco Products Directive’ laws, currently being discussed in Brussels, will act as the benchmark for vaping policies globally.
“There is a risk that global leaders at COP 9 and at EU level - under pressure from anti-vaping activists - will introduce laws that would treat vaping the same as smoking” according to Landl. “This would spell disaster for vapers, for smokers and for public health. Millions of vapers may be forced back to smoking due to tax hikes, flavour bans, and other restrictions on vaping accessibility.”
“If they ignore that vaping is 95% less harmful than smoking and has already helped millions to quit smoking, then they will miss a golden opportunity to save lives. Nearly 200 million lives can be saved if the right vaping policies are introduced, and 2021 is an absolutely critical year if this is to be achieved,” Michael Landl added.
The World Vapers’ Alliance is launching a global campaign today to make sure that the voices of the millions of vapers who have successfully beaten smoking thanks to vaping are heard. The Back Vaping. Beat Smoking campaign will deliver a clear message to all the decision-makers around the world: The best way we can beat smoking is to promote vaping as part of public health policies.
“It’s vital that vapers' voices are heard. That’s why we’re taking our campaign out on the road, across Europe and around the world. Our campaign will combine digital and real-world activism to ensure that Governments take the opportunity to ‘Back Vaping. Beat Smoking’,” Michael Landl concluded.
ENDS
---
Notes to editor:
- The World Vapers’ Alliance represents 23 vapers associations as well as 14.000 individual vapers from all over the world.
- Next FCTC COP9 meeting will be held 8–13 November 2021.
- The European Commission’s report on assessing the application of the rules laid down in the Tobacco Products Directive 2014/40/EU (TPD) was published on 20 May 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629006043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
